Catalyst Biosciences (NASDAQ:CBIO) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.08) by ($0.18), Bloomberg Earnings reports.
Shares of Catalyst Biosciences stock traded up $0.21 on Friday, reaching $8.41. The company’s stock had a trading volume of 7,861 shares, compared to its average volume of 213,754. The stock has a market capitalization of $104.18 million, a PE ratio of -3.14 and a beta of 2.46. Catalyst Biosciences has a 52-week low of $6.20 and a 52-week high of $29.95.
CBIO has been the subject of a number of analyst reports. CIBC initiated coverage on Catalyst Biosciences in a report on Friday, January 4th. They issued an “outperform” rating and a $24.00 price target for the company. Zacks Investment Research downgraded Catalyst Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, March 12th. Finally, Oppenheimer started coverage on Catalyst Biosciences in a report on Friday, January 4th. They issued an “outperform” rating and a $24.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $21.50.
About Catalyst Biosciences
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
Featured Article: Moving Average (MA)
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.